| BASIC SCIENCE STUDY |
|
| Year : 2010 | Volume
: 3
| Issue : 1 | Page : 26-35 |
|
|
A biomarker panel to discriminate between systemic inflammatory response syndrome and sepsis and sepsis severity
Chamindie Punyadeera1, E Marion Schneider2, Dave Schaffer3, Hsin-Yun Hsu4, Thomas O Joos4, Fabian Kriebel2, Manfred Weiss5, Wim FJ Verhaegh1
1 Department of Molecular Diagnostics, Philips Research, High Tech Campus 12a, 5656 AE Eindhoven, Netherlands
2 Experimental Anesthesiology, University Hospital Ulm, Steinhoevelstr. 9, 89075 Ulm, Germany
3 Philips Research North America, 345 Scarborough Road, Briarcliff Manor, NY 10510, USA
4 Natural and Medical Sciences Institute, University of Tuebingen, Markwiesenstr. 55, 72770 Reutlingen, Germany
5 Clinical Anesthesiology, University Hospital Ulm, Steinhoevelstr. 9, 89075 Ulm, Germany
Correspondence Address:
Chamindie Punyadeera
Department of Molecular Diagnostics, Philips Research, High Tech Campus 12a, 5656 AE Eindhoven
Netherlands
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0974-2700.58666
|
|
|
Introduction: In this study, we report on initial efforts to discover putative biomarkers for differential diagnosis of a systemic inflammatory response syndrome (SIRS) versus sepsis; and different stages of sepsis. In addition, we also investigated whether there are proteins that can discriminate between patients who survived sepsis from those who did not. Materials and Methods: Our study group consisted of 16 patients, of which 6 died and 10 survived. We daily measured 28 plasma proteins, for the whole stay of the patients in the ICU. Results: We observed that metalloproteinases and sE-selectin play a role in the distinction between SIRS and sepsis, and that IL-1α, IP-10, sTNF-R2 and sFas appear to be indicative for the progression from sepsis to septic shock. A combined measurement of MMP-3, -10, IL-1α, IP-10, sIL-2R, sFas, sTNF-R1, sRAGE, GM-CSF, IL-1β and Eotaxin allows for a good separation of patients that survived from those that died (mortality prediction with a sensitivity of 79% and specificity of 86%). Correlation analysis suggests a novel interaction between IL-1a and IP-10. Conclusion: The marker panel is ready to be verified in a validation study with or without therapeutic intervention |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
